Can genetic markers guide better cancer treatment?

NCT ID NCT05145244

Recruiting now Knowledge-focused Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This observational study is following about 2,400 adults with non-small cell lung cancer or breast cancer to see how biomarkers, including whole-genome sequencing, relate to their outcomes. Participants receive their usual cancer care, and researchers track progression-free survival, overall survival, quality of life, and side effects. The goal is to understand if certain biological markers can help predict how well treatments work, potentially leading to more personalized cancer care in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors predict which cancer treatments work best for individual patients, leading to more personalized care.
What could go wrong: This is an observational study, so it cannot prove cause and effect. Results may take years and might not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.